Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.
Inclusion Criteria:
Exclusion Criteria:
Already on dopamine agonist/antagonist therapy for another condition Parkinson's disease Lewy body dementia Men with QTc > 450 Women with QTc > 460 Patients with documented allergy to haloperidol Patients with known functional prolactinomas Patients who are breastfeeding Patients under the age of 18 Patients who are pregnant Patients who are in the prison system Patients who are unable to consent
mbartman@uic.edu8178972205
Patients in this arm of the study will receive haloperidol to be used as needed on an outpatient basis
weilbert@uic.edu6302944225
Chicago, Illinois 60612, United States
mbartman@uic.edu8178972205
weilbert@uic.edu6302944225
Haloperidol for the Treatment of Nausea and Vomiting in the ED
Treatment Strategies in CHS
Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department
Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis
Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)
Droperidol on Prevention of Cannabis Hyperemesis Syndrome
IV Haloperidol for the Treatment of Headache in the ED
Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department